drugset / Trial / NCT07365592
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
Phase 1/2
Recruiting
138 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
RandomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.
Timeline
- Start
- 2026-04-09
- Primary completion
- 2029-12-01
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |
| Subject | Sitagliptin | Small molecule | 200 mg | Oral |
| Subject | Sitagliptin | Small molecule | 400 mg | Oral |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |